TY - JOUR
T1 - NY-ESO-1 (CTAG1B) expression in mesenchymal tumors
AU - Endo, Makoto
AU - De Graaff, Marieke A.
AU - Ingram, Davis R.
AU - Lim, Simin
AU - Lev, Dina C.
AU - Briaire-De Bruijn, Inge H.
AU - Somaiah, Neeta
AU - Bovée, Judith V.M.G.
AU - Lazar, Alexander J.
AU - Nielsen, Torsten O.
N1 - Funding Information:
We thank Christine Chow for her excellent technical assistance. We thank Anne-Marie Cleton-Jansen, Dorien van der Geest, Marieke Kuijjer, Danielle Meijer, Jolieke van Oosterwijk, and Heidi van Paassen for the help with the construction of the LUMC tissue micro arrays and the collection of the clinical data. We would like to thank EuroBoNeT partners Nick Athanasou, the University of Oxford, UK; Soren Daugaard, Department of Pathology, RH, Denmark, Bernadette Liegl, Department of Pathology, Medizinische Universität Graz, Austria and Pierro Picci, Department of Pathology, Rizzoli Institute, Bologna, Italy for providing cases of rare chondrosarcoma subtypes. We also thank Samuel Leung for building the online relational database. Specimen access was provided through the BC Bone and Soft Tissue Tumour Bank (protocol H08-01717). This work was supported by grants from the Canadian Cancer Society Research Institute (Grant #701582), the Japan Society for the Promotion of Science KAKENHI (Grant #25893168, #26713046), a grant from the Fukuoka Foundation for Sound Health and an International Collaborative Grant from the Liddy Shriver Sarcoma Initiative.
PY - 2015/4/8
Y1 - 2015/4/8
N2 - New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90% of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1.
AB - New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90% of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1.
UR - https://www.scopus.com/pages/publications/84926520805
U2 - 10.1038/modpathol.2014.155
DO - 10.1038/modpathol.2014.155
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25412843
AN - SCOPUS:84926520805
SN - 0893-3952
VL - 28
SP - 587
EP - 595
JO - Modern Pathology
JF - Modern Pathology
IS - 4
ER -
SDG 3 Good Health and Well-being